KTTA - Pasithea Therapeutics Analyst Forecast Prices
The Pasithea Therapeutics (KTTA) market valuation chart on the GURU.Markets platform shows a value of 3.01, while the business is building a comprehensive psychological support environment by combining specialized centers with the development of new drugs. The strategy relies on multi-year patent protection for formulas treating severe pathologies, and human capital is provided by a strong team of biochemists dedicated to long-term scientific objectives.
Analytical breakdowns for Pasithea Therapeutics (KTTA)
- stock value and consensus price forecast:
- market capitalization statistics:
- book capitalization information:
- business debt structure and liquidity details:
Debt to Equity Ratio Pasithea Therapeutics|KTTA - Long-Term Debt to Capital|Current Liabilities to Capital pasitheaclinics.com|KTTA - Company Total Debt|Debts to Book Capitalization Pasithea|KTTA - Company Long-Term Debt|Company Short-Term Loans and Borrowings Pasithea Therapeutics|Immediate Liquidity pasitheaclinics.com
- earnings and market ratios statistics:
KTTA - Company Net Income|Forward Earnings Pasithea Therapeutics|KTTA - P/E Multiple|Forward P/E Multiple pasitheaclinics.com|KTTA - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Pasithea|KTTA - Operating profit EBITDA|Net earnings per share for the last four quarters Pasithea Therapeutics|KTTA - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months pasitheaclinics.com|KTTA - Earnings growth in current year|Expected earnings per share trend next year Pasithea Therapeutics
Summary company analytics:KTTA Pasithea Therapeutics Corp
This indicator represents the aggregated business value, reflecting the dynamic restructuring of analysts' valuation models based on macroeconomics and cash flows. By assessing asset resilience through the consolidated target forecasts of investment banks, investors can track how contract line utilization and the calibration of sterile equipment at Pasithea Therapeutics (KTTA) impact the fundamental attractiveness of the company's shares.
Competitors of Pasithea Therapeutics
Analyst Consensus Forecast biogen.com (BIIB)|Neurocrine Biosciences, Inc. - Consensus Target|Analyst Forecast Prices RGC (Regencell Bioscience Ltd)|AXSM: Consensus Target|ACADIA Corp - Analyst Forecast Prices|XENE: Analyst Consensus Forecast|vikingtherapeutics.com (VKTX) - Analyst Consensus Forecast|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast amylyx.com AMLX|TRVI - Price Target Chart|Fair Value Consensus PRAX (Praxis Precision Medicines Inc)|Anavex Corp (AVXL) - Price Target Chart|Average Forecast Price CeriBell EEG (CBLL)|Price Target Chart Prothena Corporation PLC|Alector Therapeutics - Forecast Levels Chart|Analyst Consensus Forecast ANNX|Analyst Consensus Forecast omeros.com (OMER)|Price Target Chart Neurogene Corp NGNE|Analyst Median Target AC Immune Inc (ACIU)|Voyager Therapeutics - Analyst Consensus Forecast|Analyst Median Target neumoratx.com NMRA|SCLX (Scilex) - Consensus Target|TVGN: Analyst Forecast Prices|ACOG (Alpha Cognition Inc) - Analyst Consensus Forecast|CGTX: Fair Value Consensus|Analyst Consensus Forecast IKT|SAVA - Average Forecast Price|Analyst Consensus Forecast ASRT (Assertio)|Analyst Consensus Forecast Coya Therapeutics Inc COYA|VTGN: Consensus Target|Fair Value Consensus OVID (Ovid Therapeutics Inc.)|ABOS (Acumen Pharmaceuticals) - Consensus Target|CRVO: Analyst Forecast Prices|ATHE (Alterity Therapeutics Ltd.) - Analyst Consensus Forecast|CLNN: Fair Value Consensus|Analyst Consensus Forecast PEPG|JUNS - Average Forecast Price|Price Target Chart Relmada Therapeutics RLMD|Fair Value Consensus ANVS|Grace Tx - Analyst Consensus Forecast|AIFF - Analyst Consensus Forecast|anewmeds.com (KLTO) - Price Target Chart|Forecast Levels Chart NRSN (NeuroSense Therapeutics Ltd.)|RVPH (Reviva Pharmaceuticals) - Analyst Consensus Forecast|Average Forecast Price MetaVia, Inc. MTVA|Consensus Target NRXS (NeurAxis)|Analyst Consensus Forecast heliusmedical.com (HSDT)|Passage Bio - Consensus Target|Analyst Forecast Prices NEUP (Neuphoria Therapeutics, Inc.)|Minerva Neurosciences - Analyst Consensus Forecast|Analyst Median Target athira.com ATHA|ADXN: Analyst Consensus Forecast|Consensus Target Alzamend Neuro|Price Target Chart Cyclerion Therapeutics Inc.|Protagenic (PTIX) - Analyst Median Target|Price Target Chart Cortigent, Inc. (CRGT)|Analyst Consensus Forecast avenuetx.com (ATXI)|BrainStorm Cell Therapeutics - Consensus Target|Analyst Forecast Prices CARA (Cara Therapeutics Inc.)|CHRO: Consensus Target|Eliem Therapeutics - Analyst Forecast Prices|ITCI: Analyst Consensus Forecast|longboardpharma.com (LBPH) - Analyst Consensus Forecast|Price Target Chart Marinus Pharmaceuticals, Inc.|Broker Consensus Forecast NKGN (NKGen Biotech Inc)|Analyst Consensus Forecast NRBO|SAGE - Average Forecast Price|Synaptogenix, Inc. - Consensus Target|Analyst Consensus Forecast trevena.com TRVN|VIGL - Price Target Chart|Fair Value Consensus WENA (Anew Medical Inc.)|Cerevel (CERE) - Price Target Chart
